More Help for Anti-HER2 Failure in Breast Cancer (CME/CE)

AMSTERDAM (MedPage Today) -- Women with progressive HER2-positive breast cancer lived significantly longer when treated with T-DM1, which doubled progression-free survival after two prior anti-HER2 regimens, results of a randomized trial showed.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news